<DOC>
	<DOCNO>NCT00002301</DOCNO>
	<brief_summary>To evaluate safety efficacy foscarnet induction treatment cytomegalovirus ( CMV ) retinitis AIDS patient previously suffer severe dose-limiting ganciclovir-related myelosuppression , ineligible ganciclovir treatment due myelosuppression clearly fail therapeutic response ganciclovir therapy . To assess duration clinical response . To evaluate effect quantitative CMV culture blood urine . To determine effect recovery HIV p24 antigen capture direct plasma .</brief_summary>
	<brief_title>A Study Foscarnet Treatment Cytomegalovirus ( CMV ) Eyes Patients With AIDS Who Have Not Had Success With Ganciclovir</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Ganciclovir . Exclusion Criteria Coexisting Condition : Patients follow excluded : Known allergy foscarnet . Any clinically significant pulmonary neurologic impairment ( e.g. , patient intubate comatose ) . Corneal , lens , vitreous opacification precludes examination fundi patient cytomegalovirus ( CMV ) retinitis . Concurrent Medication : Excluded : Acyclovir . Nephrotoxic agent . Patients follow excluded : Known allergy foscarnet . Any clinically significant pulmonary neurologic impairment ( e.g. , patient intubate comatose ) . Corneal , lens , vitreous opacification precludes examination fundi patient CMV retinitis . Prior Medication : Excluded within 7 day study entry : Immunomodulators . Biologic response modifier . Investigational agent . AIDS patient experience cytomegalovirus ( CMV ) retinitis may enrol meet one follow criterion : Myelosuppression : Previously suffer severe doselimiting ganciclovirrelated myelosuppression , ineligible ganciclovir treatment due myelosuppression . Ganciclovir treatment failure : Clearly fail therapeutic response ganciclovir therapy . Patients must able give informed consent . Patients present baseline absolute neutrophil count &lt; 750 cells/mm3 baseline platelet count &lt; 50000 platelets/mm3 categorize ineligible receive ganciclovir induction therapy allow enter study . Patients enter study ganciclovir toxicity receive ganciclovir therapy result either absolute neutrophil count fall &lt; 750 cells/mm3 platelet count fall &lt; 50000 platelets/mm3 two separate occasion either 1 ) ganciclovir induction regimen 7.5 mg less ganciclovir/kg/day divide dos 2 ) maintenance regimen 5 mg less ganciclovir/kg/day single dose . Patients enter study ganciclovir treatment failure meet one follow criterion : 1 ) CMV retinitis progression define section V.C.1. , i.e. , occur either end 10 21 day induction course ganciclovir ( 7.5 10.0 mg/kg/day divide dos ) 2 ) first 28 day maintenance ganciclovir therapy ( 5 mg/kg/day least 5 days/week ) maintenance therapy begin within 1. week complete induction therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 1991</verification_date>
	<keyword>Retinitis</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Cytomegalovirus Infections</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antiviral Agents</keyword>
</DOC>